Mianserin – place and role in the treatment of depression Case report
Article Sidebar
Published:
Nov 30, 2022
Keywords:
masked depression, mianserin, depressive disorder, bipolar affective disorder
Main Article Content
Abstract
The main group of drugs used in the treatment of depressive disorders are selective serotonin reuptake inhibitor, but they cannot be used in all cases. Restrictions in taking this group occur, for example, in patients with cardiac diseases. In addition, some patients are resistant to selective serotonin reuptake inhibitors. In such situations, it is recommended to use older drugs, usually as part of combination therapy. The paper presents cases of using mianserin, which belongs to the older generation of antidepressants.
Article Details
How to Cite
Parnowski , T. (2022). Mianserin – place and role in the treatment of depression. Medycyna Faktow (J EBM), 15(4(57), 451-455. https://doi.org/10.24292/01.MF.0422.13
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Łoza B, Parnowski T. Nowa depresja. Nowe leczenie. Medical Education, Warszawa 2013.
2. Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun. 2003; 17(suppl 1): 119-24.
3. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009; 65(9): 732-41.
4. Manikowska K, Mikołajczyk M, Mikołajczak P et al. The influence of mianserin on TNF-a, IL-6 and IL-10 serum levels in rats under chronic mild stress. Pharmacol Rep. 2014; 66: 22-7.
5. Kostowski W, Pużyński S. Pychofarmakologia kliniczna i doświadczalna. PZWL, Warszawa 1996.
6. Costa D, Mogos I, Toma T. Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatr Scand. 1985; 72(320): 85-92.
7. Kopera H, Fluch N, Harpf H et al. Cardiovascular effects of mianserin – a comparative study with amitriptyline and a placebo in healthy subjects Cochrane Central Register of Controlled Trials. Int J Clin Pharmacol Ther Toxicol. 1980; 18(3): 104-9.
8. Hayashi T, Yokota N, Takahashi T et al. Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 1997; 12(4): 199-205.
9. Kishi T, Iwata N. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. Int J Neuropsychopharmacol. 2014; 17(2): 343-54.
10. Davies P, Ijaz S, Williams CJ et al. Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev. 2019; 12(12): CD010557. http://doi.org/10.1002/14651858.CD010557.pub2.
11.Henssler J, Alexander D, Schwarzer G et al. Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression. A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022; 79(4): 300-12. http://doi.org/10.1001/jamapsychiatry.2021.4313.
2. Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun. 2003; 17(suppl 1): 119-24.
3. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009; 65(9): 732-41.
4. Manikowska K, Mikołajczyk M, Mikołajczak P et al. The influence of mianserin on TNF-a, IL-6 and IL-10 serum levels in rats under chronic mild stress. Pharmacol Rep. 2014; 66: 22-7.
5. Kostowski W, Pużyński S. Pychofarmakologia kliniczna i doświadczalna. PZWL, Warszawa 1996.
6. Costa D, Mogos I, Toma T. Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatr Scand. 1985; 72(320): 85-92.
7. Kopera H, Fluch N, Harpf H et al. Cardiovascular effects of mianserin – a comparative study with amitriptyline and a placebo in healthy subjects Cochrane Central Register of Controlled Trials. Int J Clin Pharmacol Ther Toxicol. 1980; 18(3): 104-9.
8. Hayashi T, Yokota N, Takahashi T et al. Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 1997; 12(4): 199-205.
9. Kishi T, Iwata N. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. Int J Neuropsychopharmacol. 2014; 17(2): 343-54.
10. Davies P, Ijaz S, Williams CJ et al. Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev. 2019; 12(12): CD010557. http://doi.org/10.1002/14651858.CD010557.pub2.
11.Henssler J, Alexander D, Schwarzer G et al. Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression. A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022; 79(4): 300-12. http://doi.org/10.1001/jamapsychiatry.2021.4313.